Breakthrough Alzheimer’s drug approval seen to renew dementia drug investments and increase the potential for digital dementia therapies – good news for Brain+
Copenhagen, Denmark, July 10, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · The US FDA has granted full approval to Lecanemab, the first ever disease modifying treatment for early Alzheimer’s disease, invented by BioArctic AB of Sweden and developed by Eisai and Biogen · Lecanemab has shown to slow brain destruction in Alzheimer’s, and after decades of drug failures in the field, experts now see a turning point to renewed investments in dementia drug research and the start of a new era of treatment · Dementia represents an immense unmet need - and there is growing